Preclinical studies characterizing the anti-migraine and cardiovascular effects of the selective 5-HT1D receptor agonist PNU-142633

Cephalalgia

Volumn 22, Issue 10, 2002, Pages 799-806

  McCall, Robert B ^a   Huff, R ^a   Chio, C L ^a   TenBrink, R ^a   Bergh, C L ^a   Ennis, M D ^a   Ghazal, N B ^a   Hoffman, R L ^a   Meisheri, K ^a   Higdon, N R ^a   Hall, E ^a  

^a PFIZER INC   (United States)

Author keywords

5 HT1D agonist; Migraine; PNU 142633

Indexed keywords

ANTIMIGRAINE AGENT; PNU 142633; SEROTONIN 1D AGONIST; SUMATRIPTAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTERY BLOOD FLOW; ARTICLE; BINDING AFFINITY; BINDING KINETICS; BRAIN BLOOD FLOW; CAROTID ARTERY; CAT; CONTROLLED STUDY; CORONARY ARTERY; CORONARY BLOOD VESSEL; DOG; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; ELECTROSTIMULATION; EXTRAVASATION; GUINEA PIG; HEART HEMODYNAMICS; HEMODYNAMIC MONITORING; MALE; MENINGEAL ARTERY; MIGRAINE; NONHUMAN; TRIGEMINAL NUCLEUS; TRIGEMINUS GANGLION; VASCULAR RESISTANCE; VASOCONSTRICTION;

ANALGESICS; ANIMALS; CARDIOVASCULAR SYSTEM; CATS; CHO CELLS; CHROMANS; CRICETINAE; DOGS; DRUG EVALUATION, PRECLINICAL; FEMALE; GUINEA PIGS; HUMANS; MALE; MIGRAINE DISORDERS; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SUMATRIPTAN;

EID: 0038634723     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.2002.00459.x     Document Type: Article

References (28)

1. Kimball RW, Friedman AP, Vallejo E. Effect of serotonin in migraine patients. Neurology (Minneap) 1960; 10:107-11.
2. Sicuteri F, Testi A, Anselmi B. Biochemical investigations in headache increase in hydroxyindoleacetic acid excretion during migraine attacks. Int Arch Allery 1961; 19:55-8.
3. 1B/1D receptor agonists in migraine: comparative pharmacology and its therapeutic implications. CNS Drugs 1998; 4:271-86.
4. Perry CM, Markham A. Sumatriptan. An updated review of its use in migraine. Drugs 1998; 55:889-922.
5. 1B receptors in human cerebral arteries: pharmacological characterization and localization with immunochemistry. Br J Pharmacol 1999; 128:1133-40.
6. Buzzi MG, Moskowitz MA, Shimizu T, Heath HH. Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharm 1991;30:1193-200.
7. Edvinsson L, Goadsby PJ. Neuropeptides in headache. Eur J Neurol 1998; 5:329-41.
8. Goadsby PJ. The pharmacology of headache. Prog Neurobiol 2000; 62:509-25.
9. Hamel E. The biology of serotonin receptors. Focus on migraine pathophysiology and treatment. Can J Neurol Sci 1999; 26 (Suppl. 3):S2-S6.
10. Hoskin KL, Kaube H, Goadsy PJ. Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism. Brain 1996; 119:1419-28.
11. Visser WJ, Ferrari MD. Sumatriptan in clinical practice. A 2-year review of its effects and limitation. In: Olesen J, Tfelt-Hansen P, editors. Headache treatments. Trial methodology and new drugs. New York: Lippincott-Raven, 1997:181-8.
12. Ottervanger JP, Hoorntje JCA, Valkenburg HA, Grobbee DE, Stricker BHC. Exercise testing in patients with chest pain to sumatriptan. Neth J Med 1998; 53:245-8.
13. 1 agonist, sumatriptan. Alimentary Pharmacol Therapeutics 1999; 13:927-36.
14. Nilsson T, Longmore J, Shaw D, Pantev E, Bard JA, Branchek T et al. Characterization of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol 1999; 372:49-56.
15. 1B receptor. Br J Pharmacol 1999; 128:730-4.
16. 1D agonists: potential new treatment for migraine without cardiovascular side effects. J Med Chem 1998; 41:2180-3.
17. Cheng YC, Prushoff WH. Relationship between the inhibition constant and the concentration of inhibitor which causes 50 percent inhibition of an enzyme reaction. Biochem Pharmacol 1973; 22:3099-108.
18. Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol 1992; 13:307-11.
19. McCall RB. Trigeminal ganglion elicited increases in nucleus trigeminal caudalis blood flow: a novel migraine model. Brain Res 1997; 775:189-92.
20. 1D agonist in patients with acute migraine. Cephalagia 2001; 23:727-32.
21. 1Dα serotonin receptor gene expression in trigeminal ganglia: implications for antimigraine drug development. Proc Natl Acad Sci USA 1994; 91:3666-9.
22. 1D receptors: pharmacology and therapeutic potential. Serotonin 1996; 1:19-29.
23. 1D receptor messenger RNA and ligand binding sites in guinea pig brain and trigeminal function: clues for function. Neuroscience 1998; 82:469-84.
24. 1D agonist, PNU-142633F. Int J Clin Pharmacol Therap 1999; 10:487-92.
25. Cortijo J, Marti-Cabrera M, Bernbeu EJ, Domenech T, Bou J, Fernandez AG et al. Characterization of 5-HT receptors on human pulmonary artery and vein: functional and binding studies. Br J Pharmacol 1997; 122:1455-63.
26. 1B/1D agonists: is there a cause for concern? Cephalalgia 1998; 18:539-45.
27. Yu X-J, Waeber C, Castanon N, Scearce K, Hen R, Macor JE et al. 5-carboxamido-tryptamine, CP-122,288 and dihydroergotame but not sumatriptan, CP-93,129 and serotonin-5-O-carboxymethyl-glycyl-tyrosinamide block dural plasma protein extravasation in knock-out mice that lack 5-hydroxytryptamine 1B receptors. Mol Pharmacol 1996; 49:761-5.
28. Roon K, Diener HC, Ellis P, Hettiarachchi J, Poole P, Christiansen I et al. CP-122288 blocks neurogenic inflammation, but it not effective in aborting migraine attacks: results of two controlled clinical studies. Cephalalgia 1997; 17:245.